Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients
Journal of Korean Medical Science
; : 1160-1163, 2016.
Article
in English
| WPRIM (Western Pacific)
| ID: wpr-13343
Responsible library:
WPRO
ABSTRACT
Peripheral T cell lymphoma (PTCL) is a heterogeneous group of aggressive lymphomas with poor prognosis. Elderly (age ≥ 65years) patients generally have impaired bone marrow function, altered drug metabolism, comorbidities, and poor functional status. Thus, treatment of elderly patients with relapsed or refractory PTCL remains a challenge for clinicians. A recent study disclosed that pralatrexate has a synergistic effect in combination with bortezomib. Weekly pralatrexate and bortezomib were administered intravenously for 3 weeks in a 4-week cycle. Of 5 patients, one achieved complete response after 4 cycles which has lasted 12 months until now. Another patient attained partial response after 2 cycles. Only 1 patient experienced grade 3 thrombocytopenia and neutropenia. Two patients suffered from grade 3 mucositis. Combination therapy with pralatrexate and bortezomib may be used as a salvage therapy for relapsed or refractory PTCL in the elderly with a favorable safety profile.
Full text:
Available
Database:
WPRIM (Western Pacific)
Main subject:
Drug Administration Schedule
/
Lymphoma, T-Cell, Peripheral
/
Drug Therapy, Combination
/
Bortezomib
/
Positron Emission Tomography Computed Tomography
/
Aminopterin
/
Neoplasm Recurrence, Local
/
Neutropenia
/
Antineoplastic Agents
Limits:
Aged
/
Humans
/
Male
Language:
English
Journal:
Journal of Korean Medical Science
Year:
2016
Document type:
Article